Bronchial Neoplasms clinical trials
The registry lists 55 studies for Bronchial Neoplasms across more than 10 countries. 11 are recruiting or about to start. 5 of them are mainly about Bronchial Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04. Counting its 3 narrower conditions too, such as Carcinoma, Non-Small-Cell Lung: 8,611 studies, 2,131 open.
Get an email when these change. Save the Bronchial Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Revolution Medicines, Inc. (6) · AstraZeneca (6) · Syndax Pharmaceuticals (3) · Eli Lilly and Company (3) · Blueprint Medicines Corporation (3) · Weill Medical College of Cornell University (2) · Qingdao Central Hospital (2) · Jiangsu HengRui Medicine Co., Ltd. (2)
What is being tested here
Drugs under test in Bronchial Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Osimertinib | 1 | 1 | 3 |
| Elironrasib | 1 | 0 | 2 |
| Olomorasib | 1 | 1 | 1 |
| Aflutinib | 1 | 1 | 1 |
| Daraxonrasib | 1 | 0 | 1 |
| Lifileucel | 1 | 0 | 1 |
| Autologous Tumor Infiltrating Lymphocytes LN-145 | 1 | 0 | 1 |
| Repotrectinib | 1 | 0 | 1 |
| Adebrelimab | 1 | 0 | 1 |
| Entinostat | 0 | 0 | 3 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · Immune checkpoint inhibitors 1 open
Coming up
6studies finish main data collection within a year2 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 6, phase 3 first
- Dec 2026Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) · Phase 3 · Qilu Pharmaceutical Co., Ltd.
- Nov 2027A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer · Phase 3 · Eli Lilly and Company
- Dec 2026Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC · Weill Medical College of Cornell University
- Mar 2027Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors · Revolution Medicines, Inc.
- Sep 2027A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer · Iovance Biotherapeutics, Inc.
- Nov 2027Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study · AstraZeneca
Who these studies take
Of the 10 Bronchial Neoplasms studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger. 1 (10%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 10 (100%) | 10 (100%) |
| 30 | 10 (100%) | 10 (100%) |
| 40 | 10 (100%) | 10 (100%) |
| 50 | 10 (100%) | 10 (100%) |
| 65 | 10 (100%) | 10 (100%) |
| 75 | 8 (80%) | 8 (80%) |
| 85 | 7 (70%) | 7 (70%) |
Across all 55 studies, recruiting or not: 15% stop at 75 or younger and 2% at 65; 5% take children; 0% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 55. Browse all 55 → or search them.
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 329 countries
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Phase 317 countries
- Veterans Affairs Lung Cancer Surgery Or Stereotactic RadiotherapyRecruitingNCT02984761Not applicable1 country
- Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.RecruitingNCT07279935Phase 41 country
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingNCT06128551Phase 1/27 countries
- Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerRecruitingNCT04614103Phase 212 countries
- A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerRecruitingNCT05361174Phase 1/21 country
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/219 countries
- Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLCRecruitingNCT06623656Phase 21 country
- A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLCRecruitingNCT06177925Phase 21 country
- Early Detection of Lung Cancer With Machine Learning Based on Routine Clinical InvestigationsNot yet recruitingNCT059075771 country
- Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.CompletedNCT05110196Phase 41 country
- Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Phase 313 countries
- Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) StudyActive, not recruitingNCT064942411 country
- A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 21 country
- Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCActive, not recruitingNCT063760841 country
- A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingNCT06606847Phase 21 country
- Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive, not recruitingNCT05462717Phase 113 countries
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/216 countries
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/211 countries
- Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesCompletedNCT05054725Phase 210 countries
- Evaluation of a New Open Source Virtual Bronchoscope Navigation SystemTerminatedNCT037458591 country
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Phase 1/213 countries
- Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsCompletedNCT04774952Phase 11 country
- Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated PatientsTerminatedNCT04512430Phase 21 country
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 110 countries
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsTerminatedNCT05241873Phase 15 countries
- Icotinib for Completed Resected IB NSCLC With EGFR MutationCompletedNCT02264210Phase 21 country
- Cryotechnique as a Diagnostic and Therapeutic Tool of Endobronchial TumorsCompletedNCT06531265Not applicable1 country
- High-flow Nasal Oxygen During Rigid Bronchoscopy Under General Anesthesia: a Randomized Controlled TrialCompletedNCT03892408Not applicable1 country
- EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR MutationsCompletedNCT03516214Phase 12 countries
- Navigated EBUS and Functional Imaging in Lung CancerCompletedNCT02745002Not applicable1 country
- A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung CancerTerminatedNCT02826161Phase 31 country
- Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung CancerCompletedNCT02904954Phase 21 country
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 21 country
- Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedNCT03989115Phase 1/22 countries
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 11 country
- Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung CancerStatus unknownNCT05104281Phase 31 country
- Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung CancerStatus unknownNCT04974879Phase 21 country
- A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCStatus unknownNCT03085069Phase 21 country
- Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsStatus unknownNCT03634982Phase 11 country
- trūFreeze® Spray Cryotherapy Patient RegistryCompletedNCT018022031 country
- Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid TumorsCompletedNCT02897778Phase 11 country
- Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid TumorsCompletedNCT02909452Phase 11 country
- Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerCompletedNCT01594398Phase 11 country
- The EPIC Trial The Elderly Patient Individualized Chemotherapy TrialStatus unknownNCT03402048Phase 31 country
- A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCCompletedNCT03134872Phase 31 country
- Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)TerminatedNCT030532976 countries
- Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)TerminatedNCT02134015Phase 310 countries
- A Phase III Trial of Recombinant Human Apo-2 Ligand for InjectionStatus unknownNCT03083743Phase 31 country